Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

HUTCHMED's New Drug Application For Sovleplenib For The Treatment Of Primary Immune Thrombocytopenia Has Been Accepted For Review And Granted Priority Review By The China

Author: Benzinga Newsdesk | January 11, 2024 02:33am

NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022
NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who have received at least one previous therapy

Posted In: HCM